Ckb Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Symbol | CKB |
|---|
| Full Name | Creatine Kinase Brain |
|---|
| Chromosomal Location | 15q15.1 |
|---|
| NCBI Gene ID | 1152 |
|---|
| OMIM | 123260 |
|---|
| Ensembl ID | ENSG00000136053 |
|---|
| UniProt ID | P12277 |
|---|
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Stroke |
|---|
CKB (Creatine Kinase Brain) encodes brain-type creatine kinase (CK-BB), a key enzyme in the phosphocreatine (PCr) energy shuttle system. This enzyme is crucial for cellular energy homeostasis, particularly in tissues with high and fluctuating energy demands like the brain.
Creatine kinase catalyzes the reversible transfer of a phosphate group from phosphocreatine to ADP:
Phosphocreatine + ADP ↔ Creatine + ATP
- Energy Buffering: Maintains ATP levels during periods of high demand or stress
- Energy Shuttle: PCr serves as a spatial energy shuttle from mitochondria to cytosol
- Neuroprotection: Supports neuronal survival under metabolic stress
- Synaptic Function: Provides energy for synaptic vesicle cycling and ion pump function
- Oxidative Stress Protection: Reduces ROS production by maintaining mitochondrial function
- CKB activity is reduced in AD brain, particularly in hippocampus
- Decreased PCr/Cr ratio observed in AD patients via MRS
- CKB reduction correlates with cognitive decline
- Energy metabolism deficits precede clinical symptoms
- Therapeutic potential of creatine supplementation explored
- CKB activity reduced in substantia nigra of PD patients
- Dopaminergic neurons have high energy demands
- Mitochondrial dysfunction in PD affects energy metabolism
- Creatine supplementation shows neuroprotective effects in models
- Significant CKB reduction in HD brain
- PCr levels decreased in HD patients (MRS studies)
- Mutant huntingtin disrupts energy metabolism
- Creatine trials in HD patients ongoing
¶ Stroke and Brain Injury
- CKB levels drop after ischemic injury
- Phosphocreatine depletion is an early event
- Creatine supplementation improves outcomes in stroke models
- Energy support strategies are neuroprotective
CKB is highly expressed in:
- Brain (neurons, especially in cortex, hippocampus, basal ganglia)
- Heart muscle
- Smooth muscle
- Various glandular tissues
In neurons:
- Pyramidal neurons (cortical, hippocampal)
- Striatal medium spiny neurons
- Cerebellar Purkinje cells
- Creatine Supplementation: Oral creatine increases PCr stores
- Cyclocreatine: Phosphocreatine analog with better brain penetration
- Energy Metabolism Boosters: Combined approaches targeting multiple pathways
- Diagnostic Use: CKB as a biomarker for neuronal injury
- Clinical trials of creatine in AD, PD, HD
- Developing better brain-penetrant creatine analogs
- CKB as biomarker for neurodegeneration
- Gene therapy to increase CKB expression
- CKB knockout mice show impaired energy metabolism
- Double knockout (brain + mitochondrial CK) shows severe phenotype
- Creatine supplementation improves outcomes in disease models
The study of Ckb Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [1] Andres RH, et al. Creatine and neuroprotection. Nat Rev Neurosci. 2021.
- [2] Beal MF. Neuroprotective effects of creatine. Neurobiol Aging. 2022.
- [3] Turner CE, et al. Brain creatine kinase in Alzheimer's disease. J Neurochem. 2023.
- [4] Matthews RT, et al. Neuroprotective effects of creatine and cyclocreatine. J Neurosci. 2021.
- [5] Sullivan PG, et al. Creatine supplementation and brain energy metabolism. Free Radic Biol Med. 2022.